HomeArticlesToday's HighlightsBridgeBio Pharma to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy at the ACC Annual Scientific Sessions
Today's Highlights
Premium

BridgeBio Pharma to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy at the ACC Annual Scientific Sessions

BridgeBio Pharma Today, March 24, 2025, BridgeBio Pharma, Inc. ( BBIO )  announced that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 s...
P

Prohost Biotech

1 min read
13
0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles
Expert analysis
Research reports

Comments (0)

Please sign in to join the discussion